Literature DB >> 4719208

A possible relationship to treatment between hepatitis-associated antigen and chronic persistent hepatitis in Hodgkin's disease.

M J Grange, S Erlinger, F Teillet, N Schlegel, J Barge, C Degott.   

Abstract

Hepatitis-associated (Australia) antigen (HAA) was detected in the sera of 16 (50%) of 33 patients with Hodgkin's disease; all of these patients had received the same treatment for approximately two years, and they had been in complete remission for at least two years. The HAA-positive patients had significantly higher levels of serum SGPT and significantly lower bromsulphalein clearance than the HAA-negative patients. Histological changes compatible with a diagnosis of chronic persistent hepatitis were found in the livers of 12 of the 16 HAA-positive patients and in five of the 17 HAA-negative patients (p < 0.05). In 128 patients with Hodgkin's disease who had received various forms of treatment and who were studied at various stages of remission, HAA was found in the sera of 42 (33%). Tests for HAA repeated four months later in positive reactors of both groups showed persisting antigenaemia. Hepatitis-associated antigen was not present in the sera of any of 36 patients with Hodgkin's disease studied when the diagnosis was first made and before treatment had begun. These observations suggest that persistence of HAA and the presence of chronic persistent hepatitis were more likely to be related to the treatment the patients had received than to the disease itself.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4719208      PMCID: PMC1412742          DOI: 10.1136/gut.14.6.433

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  Australia antigen and acute viral hepatitis.

Authors:  W T London; A I Sutnick; B S Blumberg
Journal:  Ann Intern Med       Date:  1969-01       Impact factor: 25.391

2.  Anicteric hepatitis associated with Australia antigen. Occurrence in patients with Down's syndrome.

Authors:  A I Sutnick; W T London; B J Gerstley; M M Cronlund; B S Blumberg
Journal:  JAMA       Date:  1968-09-02       Impact factor: 56.272

Review 3.  Australia antigen as a hepatitis virus. Variation in host response.

Authors:  B S Blumberg; A I Sutnick; W T London
Journal:  Am J Med       Date:  1970-01       Impact factor: 4.965

4.  S.H. antigen in haemodialysis-associated hepatitis.

Authors:  G C Turner; G B White
Journal:  Lancet       Date:  1969-07-19       Impact factor: 79.321

5.  An epidemic of hepatitis in a chronic-hemodialysis unit. Australia antigen and differences in host response.

Authors:  W T London; M Di Figlia; A Sutnick; B S Blumberg
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

6.  An antigen detected in the blood during the incubation period of serum hepatitis.

Authors:  A M Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1968-07       Impact factor: 11.205

7.  Hepatitis and leukemia: their relation to Australia antigen.

Authors:  B S Blumberg; A I Sutnick; W T London
Journal:  Bull N Y Acad Med       Date:  1968-12

8.  The role of serum hepatitis virus in chronic liver disease.

Authors:  A M Prince; R L Hargrove; G H Jeffries
Journal:  Trans Assoc Am Physicians       Date:  1969

9.  Australia antigen and hepatitis. Studies in asymptomatic people and lepromatous leprosy patient.

Authors:  B S Blumberg; L Melartin
Journal:  Arch Intern Med       Date:  1970-02

Review 10.  Hepatitis-associated antigen.

Authors:  N R Shulman
Journal:  Am J Med       Date:  1970-11       Impact factor: 4.965

View more
  4 in total

1.  The role of immunological mechanisms in acute and chronic hepatitis.

Authors:  A L Eddleston
Journal:  Postgrad Med J       Date:  1974-06       Impact factor: 2.401

2.  [Frequency of hepatitis B virus markers and antibodies to rubella viruses in patients with lymphoproliferative disorders (author's transl)].

Authors:  T Sauerbruch; G Frösner; H Theml; K Eggert; H Kaess
Journal:  Blut       Date:  1980-04

3.  Autopsy case of colocalized tumors of hepatocellular carcinoma and malignant lymphoma.

Authors:  S Shikuwa; M Ito; M Nakashima; K Hamasaki; S Naito; I Sekine; H Fujii
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

4.  Malignant lymphoproliferative disorders in chronic liver disease. Report of four cases and review of the literature.

Authors:  J Naparstek; M Eliakim
Journal:  Am J Dig Dis       Date:  1978-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.